Hereditary thrombophilia and low -molecular -weight heparin in women: useful determinants, including thyroid dysfunction, incorporating the management of treatment and outcomes of the entity

Rev Assoc Med Bras (1992). 2023 Mar 3;69(2):335-340. doi: 10.1590/1806-9282.20221445. eCollection 2023.

Abstract

Objective: Our study purposed to examine the complex relationship between low-molecular-weight heparin therapy, multiple pregnancy determinants, and adverse pregnancy outcomes during the third trimester in women with inherited thrombophilia.

Methods: Patients were selected from a prospective cohort of 358 pregnant patients recruited between 2016 and 2018 at the Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Belgrade.

Results: Gestational age at delivery (β=-0.081, p=0.014), resistance index of the umbilical artery (β=0.601, p=0.039), and D-dimer (β=0.245, p<0.001) between 36th and 38th weeks of gestation presented the direct predictors for adverse pregnancy outcomes. The model fit was examined using the root mean square error of approximation 0.00 (95%CI 0.00-0.18), the goodness-of-fit index was 0.998, and the adjusted goodness-of-fit index was 0.966.

Conclusion: There is a need for the introduction of more precise protocols for the assessment of hereditary thrombophilias and the need for the introduction of low-molecular-weight heparin.

MeSH terms

  • Female
  • Heparin, Low-Molecular-Weight* / therapeutic use
  • Humans
  • Pregnancy
  • Prospective Studies
  • Thrombophilia* / drug therapy
  • Thyroid Gland
  • Treatment Outcome

Substances

  • Heparin, Low-Molecular-Weight